- Home
- ACRS
as 11-26-2025 3:41pm EST
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | WAYNE |
| Market Cap: | 230.8M | IPO Year: | 2015 |
| Target Price: | $9.75 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $4.24 | Next Earning Date: | 11-06-2025 |
| Revenue: | $15,742,000 | Revenue Growth: | -41.87% |
| Revenue Growth (this year): | -68.17% | Revenue Growth (next year): | -5.82% |
Latest Aclaris Therapeutics Inc. News
ACRS Breaking Stock News: Dive into ACRS Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Simply Wall St.
7 days ago
Discovering Aclaris Therapeutics And Two Other Noteworthy Penny Stocks
Zacks
21 days ago
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
21 days ago
Aclaris: Q3 Earnings Snapshot
GlobeNewswire
21 days ago
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Zacks
22 days ago
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates
Simply Wall St.
25 days ago
Aclaris Therapeutics (NASDAQ:ACRS) adds US$40m to market cap in the past 7 days, though investors from three years ago are still down 83%
Zacks
a month ago
What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now?
Compare ACRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACRS Aclaris Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.